UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pourquoi l’hémophile saigne-t-il dans ses articulations ?

Annals of physical and rehabilitation medicine, 2011-10, Vol.54, p.e96-e96

Trossaert, M

2011

Volltextzugriff (PDF)

Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin‐induced thrombocytopenia

Journal of thrombosis and haemostasis, 2007-07, Vol.5 (7), p.1373-1379

2007

Volltextzugriff (PDF)

Émicizumab et prise de décision partagée chez les patients vivant avec l’hémophilie A

Le Pharmacien Clinicien, 2024-06, Vol.59 (2), p.e159-e159

2024

Volltextzugriff (PDF)

Costs and management of patients with hemophilia A in France: the Hemraude study

The European journal of health economics, 2022-02, Vol.23 (1), p.23-32

2022

Volltextzugriff (PDF)

Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-07, Vol.20 (4), p.550-558

2014

Volltextzugriff (PDF)

Clinical relevance of 3D gait analysis in patients with haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-09, Vol.24 (5), p.703-710

2018

Volltextzugriff (PDF)

Why do joints bleed in hemophilia?

Annals of physical and rehabilitation medicine, 2011-10, Vol.54, p.e97-e97

Trossaert, M

2011

Volltextzugriff (PDF)

Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-07, Vol.21 (4), p.481-489

2015

Volltextzugriff (PDF)

Évaluation de la morbidité dans le cancer de la prostate localisé des patients porteurs d’une hémophile de type A, de type B ou d’une maladie de von Willebrand

Progrès en urologie (Paris), 2019-11, Vol.29 (13), p.764-765

2019

Volltextzugriff (PDF)

European retrospective study of real‐life haemophilia treatment

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-01, Vol.23 (1), p.105-114

2017

Volltextzugriff (PDF)

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-11, Vol.17 (6), p.944-951

2011

Volltextzugriff (PDF)

New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2008-07, Vol.14 (s4), p.20-27

2008

Volltextzugriff (PDF)

Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-01, Vol.15 (1), p.365-368

2009

Volltextzugriff (PDF)

Proposition d’un modèle d’évaluation des hémostatiques chirurgicaux

Le pharmacien hospitalier & clinicien, 2014-12, Vol.49 (4), p.262-276

2014

Volltextzugriff (PDF)

Application of the isokinetic test to quantify knee muscle strength in haemophiliac patients

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-07, Vol.15 (4), p.973-975

2009

Volltextzugriff (PDF)

Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year 'real-world' experience

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-09, Vol.21 (5), p.646-652

2015

Volltextzugriff (PDF)

Modified APC resistance assay for patients on oral anticoagulants

The Lancet (British edition), 1994-12, Vol.344 (8938), p.1709-1709

1994

Volltextzugriff (PDF)

Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one‐stage and chromogenic factor VIII activity

Journal of thrombosis and haemostasis, 2011-03, Vol.9 (3), p.524-530

2011

Volltextzugriff (PDF)

Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype

Journal of thrombosis and haemostasis, 2008-03, Vol.6 (3), p.486-493

2008

Volltextzugriff (PDF)

High incidence of anti‐heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery

British journal of haematology, 1998-06, Vol.101 (4), p.653-655

1998

Volltextzugriff (PDF)

Hémophilie A acquise. Étude d’une série rétrospective monocentrique de 39 patients

La revue de medecine interne, 2013-01, Vol.34 (1), p.4-11

2013

Volltextzugriff (PDF)

von Willebrand factor collagen binding assay with a commercial kit using type III collagen in von Willebrand disease type 2

Journal of thrombosis and haemostasis, 2007-04, Vol.5 (4), p.868-870

2007

Volltextzugriff (PDF)

Management of bleeding in severe factor V deficiency with a factor V inhibitor

Vox sanguinis, 2014-07, Vol.107 (1), p.97-99

2014

Volltextzugriff (PDF)

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Thrombosis and haemostasis, 2017, Vol.117 (2), p.252-261

2017

Volltextzugriff (PDF)

Efficacy and safety of high ration HVWF/FVIII concentrate (VONCENTO (R)) for the treatment of bleeding epidodes in patients with WITH VON WILLEBRAND disease :s: the OPALE French experience

Haemophilia : the official journal of the World Federation of Hemophilia, 2022, Vol.28 (S1), p.107-108

2022

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(89)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pourquoi l’hémophile saigne-t-il dans ses articulations ?

Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin‐induced thrombocytopenia

Émicizumab et prise de décision partagée chez les patients vivant avec l’hémophilie A

Costs and management of patients with hemophilia A in France: the Hemraude study

Diagnosis and management challenges in patients with mild haemophilia A and discrepant FVIII measurements

Clinical relevance of 3D gait analysis in patients with haemophilia

Why do joints bleed in hemophilia?

Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study

Évaluation de la morbidité dans le cancer de la prostate localisé des patients porteurs d’une hémophile de type A, de type B ou d’une maladie de von Willebrand

European retrospective study of real‐life haemophilia treatment

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis

New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors

Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B

Proposition d’un modèle d’évaluation des hémostatiques chirurgicaux

Application of the isokinetic test to quantify knee muscle strength in haemophiliac patients

Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year 'real-world' experience

Modified APC resistance assay for patients on oral anticoagulants

Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one‐stage and chromogenic factor VIII activity

Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype

High incidence of anti‐heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery

Hémophilie A acquise. Étude d’une série rétrospective monocentrique de 39 patients

von Willebrand factor collagen binding assay with a commercial kit using type III collagen in von Willebrand disease type 2

Management of bleeding in severe factor V deficiency with a factor V inhibitor

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Efficacy and safety of high ration HVWF/FVIII concentrate (VONCENTO (R)) for the treatment of bleeding epidodes in patients with WITH VON WILLEBRAND disease :s: the OPALE French experience

Suchergebnisse filtern